multiple sclerosis relapsing remitting
Multiple sclerosis trials now focus beyond relapsing-remitting disease to address the progressive forms (PPMS and SPMS) where anti-inflammatory approaches have shown limited efficacy. Remyelination β€” regenerating the myelin sheath stripped away by the autoimmune attack β€” is the most transformative target in current MS research, with several promising candidates entering Phase 2.
Active trials evaluate BTK inhibitors (tolebrutinib, fenebrutinib) for progressive forms, remyelinating agents (PIPE-307, CNM-Au8), high-efficacy induction therapies (cladribine, alemtuzumab) in early aggressive disease, and CAR-T cell approaches for treatment-resistant cases. Optical coherence tomography (OCT) and neurodegeneration biomarkers are advancing as trial endpoints.
Disease Burden & Epidemiology
Multiple sclerosis (MS) affects approximately 2.8 million people worldwide, with incidence rates highest in North America, Northern Europe, and Australia — a geographic gradient that has long suggested environmental factors, including vitamin D levels and latitude, play a role alongside genetic predisposition. In the United States, the National MS Society estimates approximately 1 million people are living with MS. The disease is 2–3 times more common in women than men and typically presents between ages 20 and 50, making it a leading cause of non-traumatic neurological disability in young adults. Relapsing-remitting MS (RRMS) is the initial course in approximately 85% of cases, characterized by acute relapses followed by complete or partial recovery. Up to 80% of untreated RRMS patients transition to secondary progressive MS (SPMS) within 25 years, experiencing gradual worsening without clear relapses. Primary progressive MS (PPMS), affecting approximately 15% of patients, involves steady disability accumulation from onset with no discrete relapses. The economic burden is substantial: annual per-patient costs exceed $60,000 in the US when accounting for disease-modifying therapy, symptomatic management, and disability-related costs.
Key Research Trends & Landmark Studies
The OPERA I and II trials established ocrelizumab (Ocrevus) as the most effective anti-CD20 therapy for RRMS, and critically, ORATORIO demonstrated its benefit in PPMS β€” the first disease-modifying therapy approved for a primary progressive form of MS. The CLARITY and CLARITY Extension trials established cladribine tablets as an effective oral therapy with a unique pulsed dosing schedule. The AFFIRM trial was pivotal for natalizumab (Tysabri), demonstrating 68% relapse rate reduction versus placebo. Currently, tolebrutinib (BTK inhibitor, Sanofi) is in four Phase 3 trials simultaneously spanning RRMS, SPMS, and PPMS, representing the largest ongoing MS program. The remyelination space is particularly active: PIPE-307, a PDE1 inhibitor promoting oligodendrocyte differentiation, and elezanumab, an anti-RGMa antibody promoting neural repair, are both in Phase 2. Real-world evidence studies using MRI volumetrics and serum neurofilament light chain (NfL) as progression biomarkers are increasingly embedded in trial designs.
Patient Guide: How to Find & Join a Trial
People with all forms of MS can participate in clinical trials, though eligibility varies significantly by disease course (RRMS, SPMS, PPMS) and current therapy. Patients on high-efficacy therapies (natalizumab, ocrelizumab, alemtuzumab) may face washout period requirements before switching to trial treatment. Your most recent MRI results (T2 lesion count, gadolinium-enhancing lesions, and brain/spinal cord atrophy measurements) and your EDSS (Expanded Disability Status Scale) score β€” assessed by your neurologist β€” are the most important eligibility parameters for most trials. The National MS Society (nationalmssociety.org) maintains a clinical trial finder. MS Comprehensive Care Centers affiliated with the Consortium of MS Centers offer the widest trial access and specialist neurologists experienced in navigating treatment transitions around trial enrollment. Patients with progressive forms should specifically seek trials at PPMS/SPMS-focused academic programs, as these trials are less commonly available in community neurology practices.